Cyclic opioid peptide agonists and antagonists obtained via ring-closing metathesis.

Irena Berezowska, Carole Lemieux, Nga N Chung, Brian C Wilkes, Peter W Schiller

文献索引：Chem. Biol. Drug Des. 74 , 329-334, (2009)

全文：HTML全文

摘要

The opioid peptide H-Tyr-c[D-Cys-Phe-Phe-Cys]NH(2) cyclized via a methylene dithiother is a potent and selective mu opioid agonist (Przydial M.J. et al., J Peptide Res, 66, 2005, 255). Dicarba analogues of this peptide with Tyr, 2',6'-dimethyltyrosine (Dmt), 3-[2,6-dimethyl-4-hydroxyphenyl)propanoic acid (Dhp) or (2S)-2-methyl-3-(2,6-dimethyl-4-hydroxyphenyl)propanoic acid [(2S)-Mdp] in the 1-position were prepared. The peptides were synthesized on solid-phase by substituting d-allylglycine and (2S)-2-amino-5-hexenoic acid in position 2 and 5, respectively, followed by ring-closing metathesis. Mixtures of cis and trans isomers of the resulting olefinic peptides were obtained, and catalytic hydrogenation yielded the saturated -CH(2)-CH(2)- bridged peptides. All six Tyr(1)- and Dmt(1)-dicarba analogues retained high mu and delta opioid agonist potency and showed only slight or no preference for mu over delta receptors. As expected, the six Dhp(1)- and (2S)-Mdp(1)-dicarba analogues turned out to be mu opioid antagonists but, surprisingly, displayed a range of different efficacies (agonism, partial agonism or antagonism) at the delta receptor. The obtained results indicate that the mu versus delta receptor selectivity and the efficacy at the delta receptor of these cyclic peptides depend on distinct conformational characteristics of the 15-membered peptide ring structure, which may affect the spatial positioning of the exocyclic residue and of the Phe(3) and Phe(4) side chains.